• Integrated BioPharma swung to a $691,000 net loss for the quarter ended September 30, 2026, versus year-earlier net income of $123,000.
• Revenue fell 22% year over year to $9.91 million.
• The two largest Contract Manufacturing Segment customers accounted for approximately 88% of total revenue, compared with 87% a year earlier.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integrated BioPharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611131205ACCESSWRNAPR_____1251088) on November 13, 2026, and is solely responsible for the information contained therein.